AST5902 (trimesylate)
AST5902 trimesylate is the principal metabolite of Alflutinib (AST2818) both in vitro and in vivo. AST5902 trimesylate exerts antineoplastic activity. Alflutinib is an EGFR inhibitor[1].
Product Specifications
CAS Number
2929417-90-1
UNSPSC
12352005
Target
Drug Metabolite; EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ast5902-trimesylate.html
Purity
98.75
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
CS(=O)(O)=O.C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OCC(F)(F)F)N=C1N(C)CCNC)=O.CS(=O)(O)=O.CS(=O)(O)=O
Molecular Formula
C30H41F3N8O11S3
Molecular Weight
842.88
References & Citations
[1]Xiao-yun Liu, et al. Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer. Acta Pharmacol Sin. 2020 Oct; 41 (10) : 1366-1376.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TRC-C729735-250MG 250 mg
2-Cyanoethyl-P,P-di-1H-imidazol-1-ylphosphinate
Sign In for Pricing
View Details 
